One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

The former top vaccines official at the Food and Drug Administration criticized Health and Human Services Secretary Robert F.

Robert F Kennedy Jr's controversial views on vaccines were on display this week during an interview with CBS News in which he ...

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

When asked if the delay resulted from "personnel being shuffled" at the FDA, Kennedy attributed it to the vaccine's ...